Learn how enhanced CDX models with humanized immune systems improve preclinical-to-clinical success in emerging immuno-oncology therapies.
Cell line derived xenograft (CDX) models provide key decision-making information to allow an agent to move forward, and clients to advance their preclinical development programs in a timely and cost-effective manner.
Join us for this expert-led webinar where we will explore state-of-the-art methods to enhance CDX models by integrating a complete Tumor Microenvironment (TME) and humanizing the immune system. Discover breakthrough strategies that bridge the gap between preclinical studies and clinical applications, ensuring more reliable and actionable insights for immuno-oncology (IO) therapies.
Key Topics Include:
- Enhance tumor microenvironment (TME) in CDX models to better replicate immune-tumor interactions.
- Create humanized mouse models by engrafting human immune cells, allowing for IO therapy evaluation in a human immune context.
- Use CDX models to refine dosing schedules for immunotherapies and combination treatments, ensuring optimal efficacy.
- Utilize multiple patient-derived cell lines and genetic modifications to mimic heterogeneity and study therapy responses across different genetic backgrounds.
- Perform serial biopsies and liquid biopsies in CDX models to identify mutations and biomarkers linked to resistance.
Presenters
Director, Scientific Operations - San Diego
Crown Bioscience
Dr. Peck is a highly trained and experienced biologist specializing in drug discovery, development, and translational medicine. He received his PhD in Biomedical Sciences and Translational Medicine from Cedars-Sinai Medical Center in Los Angeles, California, under the guidance of the renowned cardiologist Dr. Eduardo Marban.
Prior to joining Crown Bioscience, Kiel worked extensively with small and medium-sized biotech companies to develop and advance their pre-clinical and IND-enabling drug discovery programs. Focusing mainly on product development and process optimization, he has shared multiple patents for novel manufacturing and bioengineering processes related to this work. He has successfully guided multiple drug discovery programs through the pre-IND process and onto successful IND filings. Kiel’s knowledge and experience in the early drug development pipeline provide him with the expertise and perspective to share with Crown Bioscience clients and collaborators.
Dr. Peck’s background in translational medicine positions him well to collaborate with Crown Bioscience clients as they advance their own programs through the rigors of science and regulatory approval. Kiel’s role at Crown Bioscience is to provide our clients with the knowledge and experience needed to help design and execute studies laser-focused on advancing their drug development platforms, regardless of their stage. From proof-of-concept and dose-finding studies through safety toxicology, biodistribution, and on to full efficacy studies. Kiel has experience in a wide range of critical IND-enabling studies that are foundational to the development and progression of new drug candidates.
Prior to joining Crown Bioscience, Kiel worked extensively with small and medium-sized biotech companies to develop and advance their pre-clinical and IND-enabling drug discovery programs. Focusing mainly on product development and process optimization, he has shared multiple patents for novel manufacturing and bioengineering processes related to this work. He has successfully guided multiple drug discovery programs through the pre-IND process and onto successful IND filings. Kiel’s knowledge and experience in the early drug development pipeline provide him with the expertise and perspective to share with Crown Bioscience clients and collaborators.
Dr. Peck’s background in translational medicine positions him well to collaborate with Crown Bioscience clients as they advance their own programs through the rigors of science and regulatory approval. Kiel’s role at Crown Bioscience is to provide our clients with the knowledge and experience needed to help design and execute studies laser-focused on advancing their drug development platforms, regardless of their stage. From proof-of-concept and dose-finding studies through safety toxicology, biodistribution, and on to full efficacy studies. Kiel has experience in a wide range of critical IND-enabling studies that are foundational to the development and progression of new drug candidates.
Production Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology.
Additional Content From Crown Bioscience
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance
In this webinar, three experts discuss best practices for ensuring specimen integrity, leveraging biobanking for oncology breakthroughs, and enriching clinical data for translational research.
Biomarkers from Bench to Bedside: Tools, Targets, and Translational Insights
Explore how new tools and strategies are advancing biomarker discovery, standardization, and translational research in oncology and beyond.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Related Content
Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability
Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.
From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.
De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.